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The discovery of PCSK9 inhibitors:
A tale of creativity and multifaceted
translational research
Ahmed Elguindy1, Magdi H Yacoub2,*
Creativity is defined as producing ostensibly out of nothing, something of Beauty, Order or
Significance, Peter Medawar (1915–1987)
Creativity is just connecting the dots, Steve Jobs (1955–2011)
Atherosclerosis, obesity, andmetabolic syndromeare closely linked and constitute, arguably, themost
menacing three conditions to modern society. Thus urgent, concerted efforts at several levels, utilising
modern tools, are required to tackle them. Translational research is a rapidly expanding branch of
science, dedicated to rapid delivery of discoveries from the bench to the bedside. The growing
importance of this specialty in our field is evidenced by the establishment of the International Society of
Cardiovascular Translational Research and its dedicated Journal by Nabil Dib and colleagues.1
The fundamental discovery of the relationship between, lipids, cholesterol and atherosclerosis was
made in the 1960s.2–4 This led to the discovery of lipid lowering drugs, including statins, which
constitute one of the blockbuster drugs of modern times. In spite of that, the toll of the three conditions
mentioned above continued almost unabated, particularly in patients with familial hypercholestero-
lemia (FH) in whom LDL apheresis and/or liver transplantation are needed in many instances to achieve
adequate reduction of LDL-cholesterol levels.5,6 The landmark discovery of the role of the LDL receptors
in lipid clearance by Goldstein and Brown (Figures 1 and 2)7,8 earned them the Nobel Prize, and opened
the door to further translational research which led to several further discoveries, including that of
Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9). In addition to establishing the role of the LDL
receptors in clearing LDL-C from the circulation, and that FH is due to a mutation in the LDL receptor
gene, Brown and Goldstein described three new cellular processes, including receptor-mediated
endocytosis (paving the way for further research into the mechanisms of vesicle transport and
cellular trafficking; work for which Rothman, Schekman and Sudhof have recently been awarded
the Nobel Prize in Medicine), receptor recycling, and feedback regulation of receptors, which led
to discovery of hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase and statins.
Several years later, the discovery of a major regulatory pathway controlling the number and
function of the LDL receptors was made by a large number of researchers working in different
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Figure 1. LDL receptor pathway of mammalian cells (from Goldstein J and Brown S. The LDL Receptor.
Arterioscler Thromb Vasc Biol. 2009;29:431–438).
fields of translational research. This was started by the massive contribution of Nabil Seidah’s
group from Montreal (Figure 3). While working on the chemistry and functions of a family of
proteins termed proprotein convertases, they identified PCSK9 encoded by a gene on chromosome 1
(Figure 4). Collaborative work with a French group showed that a gain of function mutation in that
gene was responsible for FH in a French family.9 This was followed by similar findings from Oslo.10
Figure 2. Joseph L. Goldstein and Michael S. Brown.
Figure 3. Nabil Seidah.
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Figure 4. Subcellular localization of proprotein convertases. Upon exiting the endoplasmic reticulum (ER), most
of the basic amino acid-specific proprotein convertases traverse the Golgi apparatus towards the trans-Golgi
network (TGN). The activated membrane-bound subtilisin kexin isozyme 1 (SKI1) is mostly concentrated in the
cis- andmedial-Golgi, from where it is then sent to lysosomes for degradation, and does not normally reach the
cell surface. Proprotein convertase subtilisin kexin 9 (PCSK9) is secreted from the TGN directly into the medium
as an enzymatically inactive non-covalent complex of the protease and its prosegment. Upon binding to the low-
density lipoprotein receptor (LDLR) at the cell surface, the PCSK9–LDLR complex is internalized into endosomes
and then sent to lysosomes for degradation. (from Seidah N and Prat A. The biology and therapeutic targeting of
proprotein convertases. Nat Rev Drug Discov. 2012 May;11(5):367–83).
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In contrast, findings from the Dallas Heart Study, showed that loss of function mutations in PCSK9
gene in a subset of Afro-Americans were associated with very low cholesterol levels and markedly
reduced incidence of cardiovascular disease.11 The mechanisms involved are schematically
shown in Figure 5.
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Figure 5. A: Model of PCSK9-mediated sorting of LDL receptors to lysosomes. The EGFa domain of the LDL
receptor is required for proper sorting of the LDL receptor back to the cell surface. The EGFa domain may contain
a sorting signal that interacts with an endosomal protein (green star), directing the LDL receptor back to the cell
surface on recycling endosomes (green arrows). Binding of PCSK9 might interfere with that signal, preventing
the LDL receptor from returning to the cell surface. Alternatively, PCSK9 could contain a distinct sorting signal
(red star) that results in the sorting of the PCSK9-LDL receptor complex (red arrows) to lysosomes. The gain-of-
function mutation involving S127 of PCSK9 may enhance the sorting of the PCSK9-LDL receptor complex to
lysosomes. B: The structure of the LDL receptor and PCSK9 at endosomal pH. The LDL receptor is folded back
upon itself at low pH; however, the face of the EGFa domain that binds PCSK9 is exposed. The LDL receptor-
binding site on PCSK9 is at the apex of a roughly triangular structure formed by the tripartite domain structure of
PCSK9. The D374 residue that is altered in gain-of-function PCSK mutants is located within the apical LDL
receptor-binding site, whereas the S127 residue is quite distant from the binding interface. S127 mutations do
not affect binding of PCSK9 to the LDL receptor. Gain-of-function mutations affecting residue 127 may reduce LDL
receptors by enhancing the sorting of LDL receptors to lysosomes, rather than by affecting the strength of
PCSK9-LDL receptor interactions. (figure and accompanying legend from Peterson A, Fong L and Young
S. PCSK9 function and Physiology. J Lipid Res. 2008 June; 49(6): 1152–1156).
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THE RUSH TO THE CLINIC
Not surprisingly, the above mentioned exciting findings was followed by the development of several
strategies to inhibit the protein or RNA using monoclonal antibodies (Figure 6) or RNA interference
drugs respectively,12–19 with extremely promising results in Phase 1 and 2 trials. Inhibition of
PCSK9-mediated degradation of LDL receptors by an epidermal growth factor-like repeat A (EGF-A)
peptide has also been demonstrated in a mouse model.20
THE FUTURE
The search for other means of inhibiting PCSK9 continues. Increased expression of PCSK9 has recently
been shown to be a key mechanism by which human resistin – an adipose tissue-derived adipokine –
downregulates hepatocyte LDL receptor expression,21 hence increasing the risk of atherosclerotic
cardiovascular disease.22,23 This interesting link opens the door for future research into resistin
inhibition as another strategy for inhibiting PCSK9; possibly with added pleotropic effects.24
Such drugs are expected to have a major effect on cardiovascular health, and represent a triumph
for translational research. The story stands as a prime example of creativity as defined by the late
Sir Peter Medawar, with a methodology that follows Steve Jobs’ approach.25
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Figure 6. Total cholesterol, LDL-C and HDL-C levels after injection of a neutralizing monoclonal antibody against
PCSK9 compared to a control antibody against keyhole limpet hemocyanin (KLH). Results are expressed as
mean ^ SEM. *p , 0.05; **p , 0.01; ***p , 0.001 vs. anti-KLH control antibody at the same time point, n ¼ 4
per group. (from Chan J. et al. A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces
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